

ELITE PHARMACEUTICALS INC /DE/  
Form SC 13G/A  
February 06, 2007

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
SCHEDULE 13G  
UNDER THE SECURITIES EXCHANGE ACT OF 1934  
(AMENDMENT NO. 1)

ELITE PHARMACEUTICALS, INC.  
(Name of Issuer)

COMMON STOCK, \$0.01 VALUE PAR SHARE  
(Title of Class of Securities)

28659T200  
(CUSIP Number)

DECEMBER 31, 2006  
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)  
 Rule 13d-1(c)  
 Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

PERSONS WHO ARE TO RESPOND TO THE COLLECTION OF INFORMATION CONTAINED IN THIS FORM ARE NOT REQUIRED TO RESPOND UNLESS THE FORM DISPLAYS A CURRENTLY VALID OMB CONTROL NUMBER.

SEC 1745 (12-02)

Edgar Filing: ELITE PHARMACEUTICALS INC /DE/ - Form SC 13G/A

CUSIP No. 28659T200

13G

Page 2

1.

NAMES OF REPORTING PERSONS  
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)  
  
MARK FAIN

2.

CHECK THE APPROPRIATE BOX IF A GROUP\*

3.

SEC USE ONLY

4.

CITIZENSHIP OR PLACE OF ORGANIZATION  
  
UNITED STATES OF AMERICA

NUMBER OF  
SHARES

5.

SOLE VOTING POWER

BENEFICIALLY  
OWNED BY

6.

SHARED VOTING POWER

EACH  
REPORTING

7.

SOLE DISPOSITIVE POWER

PERSON WITH:

8.

SHARED DISPOSITIVE POWER

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

10.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

12.

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

CUSIP No. 28659T200

13G

Page 3

13.

NAMES OF REPORTING PERSONS  
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

CHAD COMITEAU

14.

CHECK THE APPROPRIATE BOX IF A GROUP\*

15.

SEC USE ONLY

16.

CITIZENSHIP OR PLACE OF ORGANIZATION

UNITED STATES OF AMERICA

NUMBER OF  
SHARES

17.

SOLE VOTING POWER

BENEFICIALLY  
OWNED BY

18.

SHARED VOTING POWER

EACH  
REPORTING

19.

SOLE DISPOSITIVE POWER

PERSON WITH:

20.

SHARED DISPOSTIVE POWER

21.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

22.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

Edgar Filing: ELITE PHARMACEUTICALS INC /DE/ - Form SC 13G/A

-----  
23. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
-----

24. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
-----

-----  
CUSIP No. 28659T200

13G

Page 4  
-----

ITEM 1.

- (a) Name of Issuer: ELITE PHARMACEUTICALS, INC.  
(b) Address of Issuer's Principal Executive Offices: 165 LUDLOW AVENUE, NORTHVALE, NJ

ITEM 2.

- (a) Name of Person Filing: THIS STATEMENT IS FILED BY  
MARK FAIN AND CHAD COMITEAU.  
(b) Address of Principal Business Office or, if none, Residence:  
  
THE ADDRESS OF THE PRINCIPAL BUSINESS OFFICE OF EACH OF THE  
REPORTING PERSONS IS 237 PARK AVENUE, SUITE 900, NEW YORK, NY  
10017  
(c) Citizenship: US  
(d) Title of Class of Securities: COMMON STOCK, PAR VALUE \$0.01 PER SHARE  
(e) CUSIP Number: 28659T200

ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SS.SS.240.13D-1(B) OR  
240.13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A:

- (a)  Broker or dealer registered under section 15 of the Act (15 U.S.C.  
78o).  
(b)  Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).  
(c)  Insurance company as defined in section 3(a)(19) of the Act (15  
U.S.C. 78c).  
(d)  Investment company registered under section 8 of the Investment  
Company Act of 1940 (15 U.S.C 80a-8).  
(e)  An investment adviser in accordance with  
ss.240.13d-1(b)(1)(ii)(E);  
(f)  An employee benefit plan or endowment fund in accordance with  
ss.240.13d-1(b)(1)(ii)(F);  
(g)  A parent holding company or control person in accordance with ss.  
240.13d-1(b)(1)(ii)(G);  
(h)  A savings associations as defined in Section 3(b) of the Federal  
Deposit Insurance Act (12 U.S.C. 1813);  
(i)  A church plan that is excluded from the definition of an  
investment company under section 3(c)(14) of the Investment Company

Edgar Filing: ELITE PHARMACEUTICALS INC /DE/ - Form SC 13G/A

Act of 1940 (15 U.S.C. 80a-3);  
(j) [ ] Group, in accordance with ss.240.13d-1(b)(1)(ii)(J).

---

CUSIP No. 28659T200

13G

Page 5

---

ITEM 4. OWNERSHIP.

A. Mark Fain

- (a) Amount beneficially owned: As of December 31, 2006, Mark Fain beneficially owned 179,967 shares of Common Stock of Elite Pharmaceuticals, Inc., which he has sole voting power and sole dispositive power; (ii) 33,333 shares of Common Stock beneficially owned by Mr. Fain over which he has sole voting power and sole dispositive power; (iii) 33,000 shares of Common Stock beneficially owned by Stratford Management Money Purchase Pension Plan over which he has shared voting power and shared dispositive power; (iv) 150,000 shares of Common Stock beneficially owned by Stratford Partners, L.P. of which Mr. Fain is a Managing Member, and over which Mr. Fain has shared voting power and shared dispositive power; and (v) 150,000 convertible shares of Common Stock owned by Stratford Partners, L.P. over which Mr. Fain has shared voting power and shared dispositive power.
- (b) Percent of class: 5.9% beneficially owned by Mr. Fain. Calculation of percent ownership is based on 20,457,000 shares of Issuer's Common Stock as of December 6, 2006 as reported by the Issuer in its Form 10-K on December 12, 2006.
- (c) Number of shares as to which the person has:  
(i) Sole power to vote or to direct the vote: 213,300  
(ii) Shared power to vote or to direct the vote: 1,204,570  
(iii) Sole power to dispose or to direct the disposition of:  
(iv) Shared power to dispose or to direct the disposition of:

---

CUSIP No. 28659T200

13G

Page 6

---

B. Chad Comiteau

Edgar Filing: ELITE PHARMACEUTICALS INC /DE/ - Form SC 13G/A

- (a) Amount beneficially owned: As of December 31, 2006, Chad Comiteau beneficially owns 808,270 shares of Common Stock of Elite Pharmaceuticals, includes (i) 187,047 shares beneficially owned by Mr. Comiteau, he has sole voting power and sole dispositive power; (ii) convertible shares beneficially owned by Mr. Comiteau, he has sole voting power and sole dispositive power; (iii) shares beneficially owned by Stratford Management Money Partners, L.P. over which he has shared voting power and shared dispositive power; (iv) 808,270 shares beneficially owned by Stratford Partners, L.P. over which Mr. Comiteau is a Managing Member, and over which Mr. Comiteau has shared voting power and shared dispositive power; and (v) shares beneficially owned by Stratford Partners, L.P. over which Mr. Comiteau has shared voting power and shared dispositive power.
- (b) Percent of class: 5.9% beneficially owned by Mr. Comiteau. Calculation of ownership is based on 20,457,000 shares of Issuer's Common Stock as of December 6, 2006 as reported by the Issuer in its Form 10-K on December 12, 2006.
- (c) Number of shares as to which the person has:
- (i) Sole power to vote or to direct the vote: 219,712
  - (ii) Shared power to vote or to direct the vote: 1,210,982
  - (iii) Sole power to dispose or to direct the disposition of:
  - (iv) Shared power to dispose or to direct the disposition of:

ITEM 5-9 Not Applicable

Filing of this statement by Messrs. Fain and Comiteau shall not be deemed an admission that they beneficially own the securities reported herein as held in customer accounts at Stratford Partners, L.P. Messrs. Fain and Comiteau expressly disclaim beneficial ownership of all securities held in such customer accounts. No single client's interest as reported in the customer accounts at Stratford Partners, L.P. exceeds 5% of the outstanding Common Stock of the Issuer.

-----  
CUSIP No. 28659T200

13G

Page 7  
-----

ITEM 10. CERTIFICATION

(a) The following certification shall be included if the statement is filed pursuant to Rule 13G-1(b):

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. [X]

-----  
CUSIP No. 28659T200

13G

Page 8  
-----

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 6, 2007

Date

/s/ Mark Fain

-----  
Signature

Mark Fain

Name/Title

February 6, 2007

Date

/s/ Chad Comiteau

-----  
Signature

Chad Comiteau

Name/Title

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. SEE ss.240.13d-7 for other parties for whom copies are to be sent.

ATTENTION: INTENTIONAL MISSTATEMENTS OR OMISSIONS OF FACT CONSTITUTE FEDERAL CRIMINAL VIOLATION

